COMMUNIQUÉS West-GlobeNewswire

Anbio Biotechnology to Participate in KeyBanc Capital Markets Healthcare Forum
17/03/2026
FRANKFURT AM MAIN, Germany, March 17, 2026 (GLOBE NEWSWIRE) -- Anbio Biotechnology (NASDAQ: NNNN) ("Anbio" or the "Company"), a global diagnostic company in in-vitro diagnostic (IVD) technologies, announced today that [...]
SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference
17/03/2026
- Preclinical data show that SLS009 lowers the apoptotic threshold in AML cells by suppressing critical survival pathways - NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“ [...]
Kestra Medical Technologies Reports Third Quarter Fiscal 2026 Financial Results
17/03/2026
KIRKLAND, Wash., March 17, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today reported financial results for the third [...]
Synergy CHC Corp. Announces Fourth Quarter and Full Year 2025 Earnings and Conference Call Information
17/03/2026
WESTBROOK, Maine, March 17, 2026 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a leading consumer health and wellness company, today announced that it plans to release financial [...]
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting
17/03/2026
WILMINGTON, Del., March 17, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that a poster with preclinical data on the Company’s oral KAT6A [...]
Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting
17/03/2026
SAN FRANCISCO, March 17, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting
17/03/2026
Unique structural features of firmonertinib enhance binding and activity against EGFR mutant proteins including ex20ins mutant proteins in cell lines and NSCLC animal models Superior anti-tumor activity of ARR-002 in [...]
Caring for the Body, PLLC Launches Physician-Led Re-Think Aging Platform to Advance a New Era of Cognitive Decline Prevention and Longevity Care
17/03/2026
Asheville, NC, March 17, 2026 (GLOBE NEWSWIRE) -- Caring for the Body, PLLC – Center for Functional Medicine, a physician-led medical practice based in Asheville, North Carolina, today announced the continued expansion [...]
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
17/03/2026
MIAMI, March 17, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and [...]
Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting
17/03/2026
WALTHAM, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer [...]
Evaxion to present new data at AACR Annual Meeting
17/03/2026
Two abstracts accepted for presentation One abstract on new additional biomarker and immunogenicity data for personalized cancer vaccine EVX-01 Another abstract on the use of Evaxion’s AI-Immunology™ platform in [...]
Enara Bio to Unveil First‑in‑Class DARKFOX‑Targeting Bispecific T Cell Engager ENA101 in Oral Presentation at AACR 2026, Showcasing Breakthrough Potential for Solid Tumor Immunotherapy
17/03/2026
Oxford, UK – March 17, 2026. Enara Bio , a pioneer in Dark Antigen® discovery and bispecific T cell engager innovation, today announced new data to be presented at the American Association for Cancer Research (AACR) [...]
Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting
17/03/2026
New clinical data from Phase 1 trial of ZW191 to be presented in an oral presentation on April 21 Preclinical data highlight combination potential for ZW191, a folate receptor alpha (FR ⍺ )-targeting antibody-drug [...]
Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026
17/03/2026
Preclinical evidence supports azenosertib ADC combinations as potential promising therapeutic strategies for Triple-Negative Breast Cancer Demonstration of Cyclin E1 protein overexpression as an indicator for poor [...]
Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial
17/03/2026
Data was published in the Online Itinerary Planner for the 2026 AACR Annual Meeting, and is scheduled to be presented at the meeting on April 19th GARDEN CITY, N.Y., March 17, 2026 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd [...]
BlossomHill Therapeutics Unveils New Pan-KRAS Inhibitor Programs and Announces Upcoming Presentations at AACR Annual Meeting 2026
17/03/2026
SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. , a privately-held, clinical-stage biopharmaceutical company focused on the design and development of next-generation medicines for cancer, [...]
Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival
17/03/2026
NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced it will [...]
Longeveron Announces 2025 Full Year Financial Results and Provides Business Update
17/03/2026
On track for third quarter 2026 top-line trial results from anticipated pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan- [...]
OraSure Highlights Significant Operational Progress and Value Creation Initiatives Following Letter from Altai Capital
17/03/2026
Company Has Demonstrated Momentum on Transformation Strategy with Significant Regulatory and Commercial Milestones Approaching in 2026 Highlights Extensive Engagement with Altai Altai Has Rejected All Settlement [...]

Pages